Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28435927 | 0.87 | DPP4 (0.45) | MAPTKMT2ADPP4 | |
| SCHEMBL25840260 | 0.85 | DPP4 (0.44) | MAPTKMT2ADPP4RAB9A | |
| SCHEMBL21985096 | 0.83 | DPP4 (0.51) | MAPTKMT2ADPP4HTT | |
| SCHEMBL21565165 | 0.83 | DPP4 (0.53) | DPP4 | |
| SCHEMBL28424221 | 0.78 | DPP4 (0.40) | DPP4 | |
| SCHEMBL21565049 | 0.78 | KDM4E (0.36) | KDM4EDPP4ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL28424229 | 0.77 | OPRK1 (0.39) | DPP4RAB9A | |
| SCHEMBL25140257 | 0.75 | TSHR (0.39) | KDM4EMAPTTSHRFKBP1AKMT2A | |
| SCHEMBL29196914 | 0.75 | DPP4 (0.55) | TSHRKMT2ADPP4TDP1L3MBTL1 | |
| SCHEMBL21985108 | 0.74 | DPP4 (0.68) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113061594-B | Transaminase mutants, immobilized transaminases and use for preparing sitagliptin | 弈柯莱生物科技(集团)股份有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-119570758-A | Aminotransferase mutant and application thereof | 浙江工业大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-118530957-A | Transaminase mutant and application thereof in synthesis of sitagliptin or intermediate | 浙江工业大学 | 2024-08-23 | — | — | CN | disclosed |
| CN-111039900-B | Preparation method of 1-morpholine-4- (2, 4, 5-trifluoro-phenyl) butane-1, 3-dione | 弈柯莱生物科技(集团)股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-111039900-B | Preparation method of 1-morpholine-4- (2, 4, 5-trifluoro-phenyl) butane-1, 3-dione | 弈柯莱生物科技(集团)股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-111039900-B | Preparation method of 1-morpholine-4- (2, 4, 5-trifluoro-phenyl) butane-1, 3-dione | 弈柯莱生物科技(集团)股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-113061594-B | Transaminase mutants, immobilized transaminases and use for preparing sitagliptin | 弈柯莱生物科技(集团)股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230203550-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203550-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| WO-2023061237-A1 | TRANSAMINASE AND USE THEREOF IN PREPARATION OF SITAGLIPTIN OR INTERMEDIATE THEREOF | 弈柯莱生物科技(上海)股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-20230103175-A1 | TRANSAMINASE MUTANT, IMMOBILIZED TRANSAMINASE AND USE IN PREPARATION OF SITAGLIPTIN | ABIOCHEM BIOTECHNOLOGY CO, LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| CN-112424171-B | Method for synthesizing sitagliptin and intermediate thereof through biocatalysis | 北京富盛嘉华医药科技有限公司 | 2023-02-28 | — | — | CN | disclosed |
| WO-2022257686-A1 | TRANSAMINASE, IMMOBILIZED TRANSAMINASE AND USE FOR PREPARING SITAGLIPTIN | 弈柯莱生物科技(上海)股份有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2021135886-A1 | TRANSAMINASE MUTANT, IMMOBILIZED TRANSAMINASE AND USE IN PREPARATION OF SITAGLIPTIN | 弈柯莱生物科技(上海)股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20210123080-A1 | METHOD FOR BIOCATALYTIC SYNTHESIS OF SITAGLIPTIN AND INTERMEDIATE THEREOF | CHINA FORTUNE WAY COMPANY (CN) | 2021-04-29 | — | — | US | disclosed |
| US-20200157587-A1 | USE OFSTEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | Abiochem Biotechnology (Group) Co., Ltd. (CN) | 2020-05-21 | — | — | US | disclosed |
| EP-3650537-A1 | USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE | Abiochem Biotechnology Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
| CN-111039900-A | Preparation method of 1-morpholine-4- (2,4, 5-trifluorophenyl) butane-1, 3-dione | 上海弈柯莱生物医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-111039900-A | Preparation method of 1-morpholine-4- (2,4, 5-trifluorophenyl) butane-1, 3-dione | 上海弈柯莱生物医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019214084-A1 | METHOD FOR BIOCATALYTIC SYNTHESIS OF SITAGLIPTIN AND INTERMEDIATE THEREOF | China Sinopharm International Corporation (CN) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210123080-A1 | METHOD FOR BIOCATALYTIC SYNTHESIS OF SITAGLIPTIN AND INTERMEDIATE THEREOF | DPP4, SI, DPP9 | KDM4E 2423/4885MAPT 4067/4885TSHR 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.